Silence Therapeutics plc

SLN Nasdaq SEC CIK 1479615
Follow Silence Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$12.4M +40.7% vs same quarter last year
EPS, diluted −$0.08 +46.7% vs same quarter last year
Operating cash flow −$12.8M −17.3% vs same quarter last year
Revenue by quarter
$25.3M
$142K
$224K
$159K
$34K
$422K
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$559K−$88.6M
FY24$43.3M−$45.3M
FY23$31.6M−$54.2M
FY22$21.7M−$50.3M
FY21--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−20000%−15000%−10000%−5000%0%5000%FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2561.5%−16292.8%−15851.5%
FY2472.7%−146.4%−104.7%
FY2359.3%−203.5%−171.4%
FY2237.8%−281.9%−232.4%
FY21---
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$62.3M
FY24−$67.9M
FY23−$49.5M
FY22−$57.2M
FY21-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Silence Therapeutics
  • Healthcare median
−20000%−15000%−10000%−5000%0%FY21FY22FY23FY24FY25
Show the numbers
YearSilence TherapeuticsHealthcare median
FY25−15851.5%−30.6%
FY24−104.7%−47%
FY23−171.4%−58%
FY22−232.4%−80.4%
FY21-−71.8%